Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Andrew W HahnDevaki Shilpa SurasiPaul V ViscuseTharakeswara K BathalaAndrew J WieleMatthew T CampbellAmado J ZuritaAmishi Y ShahEric JonaschJianjun GaoSangeeta GoswamiOmar AlhalabiPriya RaoKanishka SircarNizar M TannirPavlos MsaouelPublished in: The oncologist (2023)
A subset of patients with S/R dedifferentiation derive clinical benefit from TT after they have progressive disease on ICT. Patients with R dedifferentiation appeared to derive more benefit from TT than those with S dedifferentiation.